MCID: PRT013
MIFTS: 60

Portal Hypertension

Categories: Cardiovascular diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 76 53 29 15
Hypertension, Portal 53 44 73
Hypertension Portal 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD10 33 K76.6
ICD9CM 35 572.3
MeSH 44 D006975
NCIt 50 C3119
SNOMED-CT 68 34742003
UMLS 73 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 53 Portal hypertensionis abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries. Treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications.

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to esophageal varix and congenital hepatic fibrosis, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and PEDF Induced Signaling. The drugs Simvastatin and Nadolol have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and testes, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system �?? made up of... more...

Related Diseases for Portal Hypertension

Diseases in the Portal Hypertension family:

Portal Hypertension Due to Infrahepatic Block

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)
# Related Disease Score Top Affiliating Genes
1 esophageal varix 32.3 SST F2 ALB
2 congenital hepatic fibrosis 32.2 PKHD1 AGTR1
3 hypersplenism 32.1 THPO F2 ALB
4 gastric antral vascular ectasia 30.8 SST CTC1
5 varicose veins 30.7 VWF VEGFA F2
6 liver disease 30.7 TNF PKHD1 GPT F2 ALB
7 hepatoportal sclerosis 30.7 GPT F2
8 schistosomiasis 30.6 TNF F2 ALB
9 infantile liver failure syndrome 1 30.4 GPT F2 ALB
10 hepatic encephalopathy 30.4 TNF GPT F2 ALB
11 liver cirrhosis 30.4 ALB EDN1 F2 GPT SST THPO
12 hepatic coma 30.3 GPT F2 ALB
13 abdominal tuberculosis 30.3 F2 ALB
14 hepatitis b 30.3 ALB F2 GPT TNF
15 cholangitis 30.1 TNF GPT F2 ALB
16 cholelithiasis 30.0 SST GPT ALB
17 analbuminemia 29.9 ALB F2 GPT
18 nonalcoholic steatohepatitis 29.9 TNF GPT F2
19 alcoholic hepatitis 29.9 TNF GPT F2 ALB
20 obstructive jaundice 29.9 ALB EDN1 F2 GPT TNF
21 active peptic ulcer disease 29.9 VWF F2
22 hepatorenal syndrome 29.8 F2 EDN1 ALB
23 angiodysplasia 29.8 VWF VEGFA SST
24 connective tissue disease 29.8 BMPR2 EDN1 EDNRA TNF
25 myeloma, multiple 29.8 VEGFA TNF JAK2 ALB
26 hepatic tuberculosis 29.7 GPT F2 ALB
27 kwashiorkor 29.7 GPT F2 ALB
28 peritonitis 29.7 TNF F2 ALB
29 choledocholithiasis 29.7 ALB F2 GPT
30 acute liver failure 29.7 ALB F2 GPT
31 cholecystitis 29.7 ALB F2 GPT
32 hepatopulmonary syndrome 29.6 ALB BMPR2 EDN1 NOS3 TNF VEGFA
33 kidney disease 29.6 AGTR1 ALB EDN1 EDNRA NOS3 PKHD1
34 pulmonary hypertension 29.6 BMPR2 EDN1 EDNRA NOS3 UTS2 VWF
35 autosomal dominant polycystic kidney disease 29.5 ALB EDN1 EDNRA NOS3 PKHD1 VEGFA
36 viral hepatitis 29.5 TNF GPT F2 ALB
37 dilated cardiomyopathy 29.1 AGTR1 ALB EDN1 EDNRA NOS3 TNF
38 hepatic vascular disease 29.1 ALB EDN1 F2 JAK2 NOS3 SST
39 vascular disease 29.0 ALB BMPR2 EDN1 F2 NOS3 TNF
40 heart disease 28.2 AGTR1 ALB BMPR2 EDN1 EDNRA F2
41 portal hypertension, noncirrhotic 12.7
42 colonic varices without portal hypertension 12.2
43 portal hypertension due to infrahepatic block 12.2
44 nodular regenerative hyperplasia 12.1
45 banti's syndrome 11.8
46 splenomegaly 11.4
47 polycystic kidney disease 4 with or without polycystic liver disease 11.3
48 caroli disease 11.3
49 portal vein thrombosis 11.3
50 myelofibrosis 11.2

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Failure
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 AGTR1 ALB BMPR2 CTC1 EDN1 EDNRA
2 growth/size/body region MP:0005378 10.29 AGTR1 BMPR2 CTC1 EDN1 EDNRA F2
3 hematopoietic system MP:0005397 10.27 AGTR1 BMPR2 CTC1 EDNRA F2 JAK2
4 immune system MP:0005387 10.27 AGTR1 BMPR2 CTC1 EDNRA F2 JAK2
5 cardiovascular system MP:0005385 10.26 AGTR1 BMPR2 EDN1 EDNRA F2 NOS3
6 cellular MP:0005384 10.25 ALB BMPR2 CTC1 EDNRA JAK2 NOS3
7 mortality/aging MP:0010768 10.25 AGTR1 ALB BMPR2 CTC1 EDN1 EDNRA
8 digestive/alimentary MP:0005381 10.24 ALB EDN1 EDNRA F2 NOS3 PKHD1
9 endocrine/exocrine gland MP:0005379 10.18 ALB CTC1 EDN1 EDNRA JAK2 NOS3
10 nervous system MP:0003631 10.06 AGTR1 BMPR2 EDN1 EDNRA F2 NOS3
11 liver/biliary system MP:0005370 9.98 ALB JAK2 NOS3 PKHD1 TNF UTS2
12 normal MP:0002873 9.96 ALB BMPR2 EDN1 EDNRA F2 JAK2
13 muscle MP:0005369 9.91 ALB BMPR2 EDN1 EDNRA NOS3 TNF
14 renal/urinary system MP:0005367 9.76 AGTR1 ALB BMPR2 EDN1 EDNRA NOS3
15 respiratory system MP:0005388 9.5 BMPR2 EDNRA F2 NOS3 PKHD1 TNF
16 skeleton MP:0005390 9.32 BMPR2 EDN1 EDNRA F2 GPT JAK2

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
2
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
3
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
4
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
5
Prazosin Approved Phase 4 19216-56-9 4893
6
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 10102-43-9 145068
7
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
8
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
9
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable 52-01-7, 1952-01-7 5833
10
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
11
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
12
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 6691 54678486
13
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
14
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
15
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
16
Dipyridamole Approved Phase 4 58-32-2 3108
17 tannic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable
18
Dalteparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6
19
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
20
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
21
Nadroparin Approved, Investigational Phase 4,Not Applicable
22
Lypressin Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-57-7
23
Terlipressin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 14636-12-5 72081
24
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
25
Colchicine Approved Phase 4,Phase 2,Not Applicable 64-86-8 6167 2833
26
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
27
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 54-31-9 3440
28
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83150-76-9 383414 6400441
29
Lactulose Approved Phase 4,Phase 2,Not Applicable 4618-18-2 11333
30
Tranexamic Acid Approved Phase 4 1197-18-8 5526
31
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
32
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
33 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
38 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
40 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
44 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
46 isosorbide-5-mononitrate Phase 4,Not Applicable
47 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Sympatholytics Phase 4
50 Nitric Oxide Donors Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 278)
# Name Status NCT ID Phase Drugs
1 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
2 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
3 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
4 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
6 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
7 Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
8 Preventing Recurrent Bleeding After Eradication of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
9 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
10 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
11 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
12 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
13 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
14 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
15 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
16 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
17 Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
18 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
19 Short Course Terlipressin for Control of Acute Variceal Bleeding Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
20 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
21 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
22 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
23 The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Completed NCT00534677 Phase 4 Terlipressin;Octreotide
24 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4 Albumin
25 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
26 Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis Recruiting NCT02907749 Phase 4 Spironolactone;Carvedilol
27 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
28 Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population Recruiting NCT03769597 Phase 4 Iohexol Inj 300 MG/ML
29 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Enrolling by invitation NCT02925975 Phase 4 Carvedilol
30 Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Not yet recruiting NCT02945956 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu
31 Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir Not yet recruiting NCT02945982 Phase 4 Entecavir+Carvedilol+ Placebo;Entecavir+Carvedilol+ Fuzheng Huayu;Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis
32 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
33 Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
34 Sodium Restriction in the Management of Cirrhotic Ascites Terminated NCT00548366 Phase 4
35 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
36 Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension Unknown status NCT02975323 Phase 3 Carvedilol
37 Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
38 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
39 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
40 Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
41 HR Versus RFA for HCC in Patients With PHT Unknown status NCT02192671 Phase 3
42 Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC Unknown status NCT02338297 Phase 3 EGM;PVA
43 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
44 ¹³C-Methacetin Breath Test (MBT) Methodology Study Unknown status NCT01205074 Phase 2, Phase 3 Non selective beta blocker - Propranolol
45 TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV Unknown status NCT02853526 Phase 3 Propranolol;Warfarin
46 Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH) Completed NCT01000779 Phase 3 Propranolol
47 Simvastatin Effect on Portal Hypertension Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
48 Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
49 Danish Carvedilol Study in Portal Hypertension Completed NCT00493480 Phase 3 carvedilol;propranolol
50 Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Completed NCT00331188 Phase 3 Sanvar® (vapreotide)

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

41
Liver, Spleen, Testes, Endothelial, Heart, Pancreas, Kidney

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 1861)
# Title Authors Year
1
Use of Iodized Oil and Gelatin Sponge Embolization in Splenic Artery Coiling Reduces Bleeding from Laparoscopic Splenectomy for Cirrhotic Portal Hypertension Patients with Complicating Hypersplenic Splenomegaly: A Comparative Study. ( 29608435 )
2018
2
Torsion of a wandering spleen as a cause of portal hypertension and mesenteric varices: a rare aetiology. ( 29876050 )
2018
3
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? Author's reply. ( 29341273 )
2018
4
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension. ( 29970660 )
2018
5
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. ( 29781346 )
2018
6
Impact of patatin-like phospholipase domain containing 3 rs738409A G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. ( 29956823 )
2018
7
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. ( 29326427 )
2018
8
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor I+/I^ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. ( 29929914 )
2018
9
Managing portal hypertension in patients with liver cirrhosis. ( 29780579 )
2018
10
The "caput medusae" sign in portal hypertension. ( 29450607 )
2018
11
Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. ( 29391766 )
2018
12
Liver stiffness better predicts portal hypertension after HCV eradication. ( 29922768 )
2018
13
Doppler assessment of children with liver cirrhosis and portal hypertension in comparison with a healthy control group: An analytical cross-sectional study. ( 29937902 )
2018
14
Endoscopic linear stapler-assisted resection of a giant solid pseudopapillary pancreatic tumor with concurrent regional portal hypertension: a case report. ( 29865921 )
2018
15
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? ( 29341272 )
2018
16
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. ( 29977287 )
2018
17
Periampullary Variceal Bleeding: An Atypical Complication of Portal Hypertension. ( 29854492 )
2018
18
Portal hypertension and hypersplenism in extrahepatic portal venous obstruction: Are they related? ( 29936618 )
2018
19
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
20
Bleeding stomal varices in portal hypertension. ( 29904472 )
2018
21
Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension. ( 29854501 )
2018
22
Editorial: the portal hypertension puzzle-spleen stiffness evades validation as non-invasive marker of clinically significant portal hypertension. ( 29446131 )
2018
23
Ten-year experience of transjugular intrahepatic portosystemic shunt for noncirrhotic portal hypertension. ( 29324586 )
2018
24
TMEM16A regulates portal vein smooth muscle cell proliferation in portal hypertension. ( 29434696 )
2018
25
Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After Radiotherapy and Systemic Chemotherapy. ( 29743803 )
2018
26
Letter: high oral dose of taurine for portal hypertension in cirrhotic patients-some clinical pharmacology considerations. ( 29446135 )
2018
27
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. ( 29377193 )
2018
28
Ectopic varices: a potential cause of gastrointestinal bleeding in patients with portal hypertension. ( 29909391 )
2018
29
APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure. ( 29274906 )
2018
30
Non-cirrhotic portal hypertension: A possibly benign but complicated disease. ( 29935993 )
2018
31
Massive Epithelioid Hemangioendothelioma Causing Noncirrhotic Portal Hypertension. ( 29609064 )
2018
32
Laparoscopic splenectomy and subsequent oncologic gastric surgery in cirrhotic patients with portal hypertension and hypersplenism. ( 29391322 )
2018
33
Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. ( 29322599 )
2018
34
Intentional Modulation of Portal Venous Pressure by Splenectomy Saves the Patient with Liver Failure and Portal Hypertension After Major Hepatectomy: Is Delayed Splenectomy an Acceptable Therapeutic Option for Secondary Portal Hypertension? ( 29410393 )
2018
35
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. ( 29368385 )
2018
36
Surveillance for portal hypertension in the course of liver cirrhosis. ( 29904721 )
2018
37
Point Shear Wave Elastography of the Spleen: Its Role in Patients with Portal Hypertension. ( 29352618 )
2018
38
Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. ( 29449343 )
2018
39
Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients. ( 29900587 )
2018
40
Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. ( 29858640 )
2018
41
Portal hypertension and chylous ascites complicating acute pancreatitis: the therapeutic value of portal vein stenting. ( 29046075 )
2018
42
Obliterative Portal Venopathy without Cirrhosis is Prevalent in Pediatric Cystic Fibrosis Liver Disease with Portal Hypertension. ( 30404037 )
2018
43
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. ( 30344420 )
2018
44
Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. ( 30348829 )
2018
45
Laparoscopic splenectomy: posterolateral approach in patients with liver cirrhosis and portal hypertension with platelet count lower than 1 × 109/l. ( 30524615 )
2018
46
Splenic Bed Laparoscopic Splenectomy Approach for Massive Splenomegaly Secondary to Portal Hypertension and Liver Cirrhosis. ( 29981644 )
2018
47
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. ( 30197479 )
2018
48
ACE I allele is associated with more severe portal hypertension in patients with liver cirrhosis: A pilot study. ( 30236768 )
2018
49
Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. ( 29470765 )
2018
50
Pregnancy in a patient with portal hypertension secondary to liver cirrhosis. ( 29507022 )
2018

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 AGTR1 BMPR2 EDN1 EDNRA F2 JAK2
2
Show member pathways
13.47 BMPR2 EDN1 EDNRA F2 JAK2 NOS3
3
Show member pathways
13.08 ALB F2 JAK2 NOS3 THPO VEGFA
4
Show member pathways
12.67 AGTR1 EDN1 F2 JAK2 NOS3 TNF
5
Show member pathways
12.25 AGTR1 F2 JAK2 NOS3 TNF
6 11.77 JAK2 TNF VEGFA
7 11.69 EDN1 NOS3 VEGFA
8
Show member pathways
11.66 F2 THPO VWF
9 11.5 BMPR2 EDN1 NOS3 TNF VEGFA
10 11.31 EDN1 NOS3 VEGFA
11 11.27 EDN1 EDNRA JAK2
12 11.1 AGTR1 EDN1 JAK2 NOS3 TNF VEGFA
13 10.96 EDN1 EDNRA NOS3
14
Show member pathways
10.81 EDN1 JAK2 VEGFA

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ALB EDN1 F2 SST THPO TNF
2 caveola GO:0005901 9.5 BMPR2 JAK2 NOS3
3 platelet alpha granule lumen GO:0031093 9.43 ALB VEGFA VWF
4 extracellular space GO:0005615 9.32 ALB BMPR2 EDN1 F2 GPT SST
5 Weibel-Palade body GO:0033093 8.96 EDN1 VWF

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.81 EDN1 EDNRA NOS3 VEGFA
2 kidney development GO:0001822 9.8 AGTR1 PKHD1 VEGFA
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.79 EDN1 JAK2 TNF
4 positive regulation of inflammatory response GO:0050729 9.77 AGTR1 JAK2 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.76 F2 THPO TNF VEGFA
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 F2 JAK2 TNF
7 regulation of inflammatory response GO:0050727 9.74 AGTR1 JAK2 TNF
8 positive regulation of cell proliferation GO:0008284 9.73 EDN1 F2 JAK2 PKHD1 THPO VEGFA
9 positive regulation of MAP kinase activity GO:0043406 9.72 EDN1 TNF VEGFA
10 positive regulation of cytosolic calcium ion concentration GO:0007204 9.67 AGTR1 EDN1 EDNRA JAK2
11 blood coagulation, intrinsic pathway GO:0007597 9.62 F2 VWF
12 vasoconstriction GO:0042310 9.62 EDN1 EDNRA
13 regulation of blood vessel diameter GO:0097746 9.61 AGTR1 UTS2
14 positive regulation of endothelial cell migration GO:0010595 9.61 BMPR2 EDN1 VEGFA
15 artery smooth muscle contraction GO:0014824 9.59 EDN1 EDNRA
16 negative regulation of platelet activation GO:0010544 9.58 F2 NOS3
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.58 EDN1 JAK2 TNF
18 endothelial cell apoptotic process GO:0072577 9.56 BMPR2 TNF
19 positive regulation of axon extension involved in axon guidance GO:0048842 9.54 BMPR2 VEGFA
20 regulation of glucose transmembrane transport GO:0010827 9.52 EDN1 EDNRA
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 EDN1 JAK2 TNF
22 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.49 EDN1 NOS3
23 branching involved in blood vessel morphogenesis GO:0001569 9.33 EDN1 EDNRA VEGFA
24 regulation of blood pressure GO:0008217 9.26 EDN1 EDNRA NOS3 UTS2
25 regulation of signaling receptor activity GO:0010469 9.17 EDN1 F2 SST THPO TNF UTS2
26 G protein-coupled receptor signaling pathway GO:0007186 10.02 AGTR1 EDN1 EDNRA F2 JAK2 SST

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 EDN1 THPO TNF VEGFA
2 signaling receptor binding GO:0005102 9.35 EDN1 F2 JAK2 THPO UTS2
3 hormone activity GO:0005179 8.92 EDN1 SST THPO UTS2

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....